Citation Impact
Citing Papers
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody
2005
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8
2004 StandoutScience
Postexposure Effects of Vaccines on Infectious Diseases
2019
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Immunotherapy of cancer in 2012
2012
Cross-Priming as a Predominant Mechanism for Inducing CD8+ T Cell Responses in Gene Gun DNA Immunization
2001
EGFR Antagonists in Cancer Treatment
2008 Standout
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Therapeutic cancer vaccines: are we there yet?
2010
mRNA Is an Endogenous Ligand for Toll-like Receptor 3
2004 StandoutNobel
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
1998
Liposome–nucleic acid immunotherapeutics
2007
DNA–based immunization by in vivo transfection of dendritic cells
1996
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2010
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
2010 StandoutNobel
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines
2012
Mitochondria: In Sickness and in Health
2012 Standout
Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas
2010 StandoutNobel
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
2017
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
RNA as a tumor vaccine: a review of the literature
2001
Cancer immunotherapy comes of age
2011 StandoutNature
Management of Metastatic Melanoma 2005
2006
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
2005 StandoutNobel
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
2008 StandoutNobel
Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA
1998 StandoutNobel
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Human Clinical Trials of Plasmid DNA Vaccines
2005
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Bisphosphonate conjugation for bone specific drug targeting
2018
DNA and RNA-based vaccines: principles, progress and prospects
1999
The BCL-2 Family Reunion
2010
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
2009
DNA Vaccines: Recent Developments and Future Possibilities
2006
Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
1998
Recent Developments in Cancer Vaccines
2011
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
2004 StandoutNobel
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
2009
Emerging Methods and Design Principles for Cell‐Penetrant Peptides
2018
Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen
2005
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Antigen Presentation by Dendritic Cells after Immunization with DNA Encoding a Major Histocompatibility Complex Class II–restricted Viral Epitope
1997 StandoutNobel
Intracellular Delivery of a Proapoptotic Peptide via Conjugation to a RAFT Synthesized Endosomolytic Polymer
2009
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy
2004
Understanding Cell Penetration of Cyclic Peptides
2019
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
1995
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Characterization of a messenger RNA polynucleotide vaccine vector.
1995
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
2021 Standout
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
1997
Cell Penetration Profiling Using the Chloroalkane Penetration Assay
2018
DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector
1998
RNA-Based Vaccines in Cancer Immunotherapy
2015
Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
2006 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
2009
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
2001
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
2009
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
2009
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group
2008
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
Contribution of Cells at the Site of DNA Vaccination to the Generation of Antigen-Specific Immunity and Memory
1998
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
2001
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Gene-based vaccines: recent technical and clinical advances
2006
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques
2007
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Noncytopathic Sindbis virus RNA vectors for heterologous gene expression
1998 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Immune checkpoint inhibitors in challenging populations
2017
A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo
1995
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
2013
Works of Robert M. Conry being referenced
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients
2016
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
2011
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
2016
Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse
2005
Human Immune Respone to Monoclonal Antibodies
1994
Responses to immune checkpoint inhibitors in nonagenarians
2016
Intratumoral Administration of a Recombinant Canarypox Virus Expressing Interleukin 12 in Patients with Metastatic Melanoma
2005
Phase I Trial of an Anti-CD19 Deglycosylated Ricin A Chain Immunotoxin in Non-Hodgkinʼs Lymphoma
1995
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
2009
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
2017
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM)
2005
A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.
1995
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
2006
Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
2015
Selected strategies to augment polynucleotide immunization.
1996
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
2002
Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors.
1994
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival
2004
Polynucleotide-mediated immunization therapy of cancer.
1996